AstraZeneca already has a Tagrisso approval for patients with previously untreated, EGFR-mutated lung cancer—and it’s already steamrolling, sales-wise. Now it’s shoring up its case with some clutch new data showing the targeted drug actually helps patients live longer. More: AstraZeneca
read moreA manufacturing mix-up can hit just as hard as a straight-up efficacy failure, and Nektar has learned that the hard way. CEO Howard Robin admitted Thursday that a couple of bad lots eroded NKTR-214’s efficacy numbers in a key trial,
read moreShareholders can be a testy bunch. Just ask Perrigo, which announced its plan to split off its prescription generics division last year after investor agitation. But with its over-the-counter business treading water, Perrigo has chosen to back away from its promise—for
read moreNovo Nordisk’s new GLP-1 med Ozempic is scooping up market share, and the company has another big approval expected yet this year in oral semaglutide. With its insulin products still suffering, that’s a welcome relief. More: Novo's Ozempic launch kicks
read moreThe number of A&E patients in England waiting on trolleys for more than four hours is the highest since records began. More: Latest performance stats show NHS is 'struggling' Source: News
read moreGood news for adult patients with gastroenteropancreatic neuroendocrine tumours. More: Ipsen launches new self-injection Somatuline option Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals